ReviewMediterranean journal of rheumatology2022
Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology.
Review in Mediterranean journal of rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- Post-bariatric surgery-associated inflammatory arthritis: a case series describing clinical and MRI features.BMC rheumatology · 2026Article
- Serum immune profiling suggests overlap between IBD patients with joint complaints and patients with spondyloarthritis.Frontiers in immunology · 2026Article
- The role of a multidisciplinary approach in the early and differential diagnosis of inflammatory bowel disease-related spondyloarthritis: insights from a cross-sectional study.Frontiers in medicine · 2026Article
- Saudi Clinical Practice Guidelines for Management of Axial Spondyloarthritis Disease.Rheumatology and therapy · 2025Article
- Rheumatic Manifestations in Patients with Idiopathic Inflammatory Bowel Disease: A Single Tertiary Centre, Interdisciplinary Study.Mediterranean journal of rheumatology · 2025Article
- Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn's disease.Journal of Crohn's & colitis · 2025Article
- Metabolic musculoskeletal disorders in patients with inflammatory bowel disease.The Korean journal of internal medicine · 2025Review
- Joint Manifestations in Inflammatory Bowel Diseases, "Red Flags" for the Early Recognition and Management of Related Arthropathies: A Narrative Review.Journal of clinical medicine · 2025Review
- Screening for Spondyloarthritis in Patients with Inflammatory Bowel Disease - SPARTAN 2024 Annual Meeting Proceedings.Current rheumatology reports · 2025Review
- New-Onset, Treatment-Resistant Inflammatory Bowel Disease after Administration of Secukinumab for Plaque Psoriasis: A Case Report and Review of the Existing Literature.Mediterranean journal of rheumatology · 2024Article
- Clinical features and fecal microbiota characteristics of patients with both ulcerative colitis and axial spondyloarthritis.BMC gastroenterology · 2024Article
- JAK Inhibitors for the Treatment of Axial Spondyloarthritis.Mediterranean journal of rheumatology · 2023Review
- Spondyloarthropathies That Mimic Ankylosing Spondylitis: A Narrative Review.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2023Review
- Exploring the common diagnostic gene KCNJ15 and shared pathway of ankylosing spondylitis and ulcerative colitis through integrated bioinformatics.Frontiers in physiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Spondyloarthritides (SpA) are a group of chronic inflammatory d iseases a ffecting th e spine, peripheral joints and entheses, as well as extra-skeletal structures, including the gastrointestinal tract. On the other hand, inflammatory b owel d isease (IBD), e ither Crohn's d isease o r ulcerative colitis, often affects extra-intestinal sites, including the axial and/or peripheral skeleton. IBD-related arthritis is the type of SpA that occurs in patients affected by IBD, with an incidence up to 50% during the IBD course. Although both manifestations are apparently the result of a common pathogenetic process, physicians often fail to recognize the disease in its entirety: thus, IBD-SpA is managed as two separate diseases, a musculoskeletal and a gastrointestinal one, with a profound impact on patient quality of life. Moreover, the specialty of the treating physician determines the clinical and laboratory tools for disease assessment, which, in turn, guide treatment decisions that may overlook either affected system or even act in the opposite direction. Raising awareness of the intestinal and musculoskeletal manifestations among rheumatologists and gastroenterologists will lead to earlier diagnosis and a multidisciplinary approach, particularly regarding pharmacologic treatments. Given the lack of trial evidence on immunomodulatory drugs in IBD-SpA it is imperative for researchers in both medical disciplines to join efforts, in order to determine referral strategies, appropriate composite measures for disease assessment, treatment algorithms and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.